Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.63 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | KIF5B | P33176 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
| ▸ | LYN | P07948 | 1/20 | 0.50 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.50 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.50 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.50 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.50 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.50 |
| ▸ | ADK | P55263 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695020 | 1.00 | EGFR (0.63) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL20695016 | 1.00 | EGFR (0.63) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL30777161 | 1.00 | EGFR (0.63) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL29904972 | 1.00 | EGFR (0.63) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL20695031 | 1.00 | EGFR (0.63) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL21481105 | 0.90 | EGFR (0.58) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL27040463 | 0.88 | EGFR (0.55) | EGFRKDREPHA2EPHB4RET | |
| SCHEMBL20695045 | 0.88 | EGFR (0.52) | EGFRKDREPHA2EPHB4FLT1 | |
| SCHEMBL20695040 | 0.88 | EGFR (0.52) | EGFRKDREPHA2EPHB4FLT1 | |
| SCHEMBL20695049 | 0.88 | EGFR (0.52) | EGFRKDREPHA2EPHB4FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2025-12-04 | — | — | US | claimed |
| CN-120091813-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2025-06-03 | — | — | CN | claimed |
| EP-4531846-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| WO-2025049814-A2 | RIBONUCLEOTIDE REDUCTASE (RNR) COMPOSITIONS AND METHODS OF USE | BOUNDLESS BIO, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| CN-118987016-A | Application of antisense oligonucleotide in preparing medicament for treating glioma | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024196923-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | BOUNDLESS BIO, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2024-04-11 | — | — | US | claimed |
| CN-117729923-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| EP-4288057-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2023235356-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2023-12-07 | — | — | WO | claimed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| CN-121586709-A | Checkpoint kinase 1 (CHK 1) inhibitor crystal forms and uses thereof | 无界生物公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | disclosed |
| EP-4688770-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITOR CRYSTALLINE FORM AND USES THEREOF | Boundless Bio, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230026313-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022251502-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | DUSP6, SOS1, DUSP1 | EGFR 20/4885KDR 670/4885EPHA2 426/4885 |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | NCOA1, AR, ESR2 | EGFR 53/4885KDR 80/4885EPHA2 441/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | EGFR 2007/4885KDR 2914/4885EPHA2 1963/4885 |
| US-20230026313-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | EGFR 2007/4885KDR 2914/4885EPHA2 1963/4885 |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | KRAS, NRAS, HRAS | EGFR 24/4885KDR 596/4885EPHA2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.